Edgar Filing: ANTIGENICS INC /DE/ - Form 4

	CS INC /DE/								
Form 4	2008								
October 03,		OMB APPROVAL							
Check t if no lor subject Section Form 4 Form 5	nger STATEN to STATEN 16. or		CHANGES II SECU	n, D.C. 20549 N BENEFICIAL O JRITIES the Securities Excha		Number: Expires: Estimated burden hou response	urs per		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
 (Print or Type Responses) 1. Name and Address of Reporting Person <u>*</u> Levitsky Hyam 			ymbol	nd Ticker or Trading INC /DE/ [AGEN]	5. Relationship of Reporting Person(s) to Issuer				
(Last) (First) (Middle) C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900			. Date of Earliest Month/Day/Year) 0/01/2008		(Check all applicable) <u>X</u> Director <u>Officer (give title</u> below) Differ (specify below)				
(Street) NEW YORK, NY 10010			. If Amendment, iled(Month/Day/Y	-	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
		(7.)			Person				
(City) 1.Title of Security (Instr. 3)	(State) 2. Transaction Date (Month/Day/Year)	(Zip) 2A. Deemed Execution Da any (Month/Day/	3. ate, if Transact Code Year) (Instr. 8)	 1-Derivative Securities 4. Securities ionAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or V Amount (D) Price 	5. Amount of Securities 1 Beneficially (Owned (Following (Reported Transaction(s) (Instr. 3 and 4)	of, or Beneficia 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Re	port on a separate lin	e for each class	s of securities ber	information con required to resp	or indirectly. espond to the collect ntained in this form bond unless the for ently valid OMB cor	are not m	SEC 1474 (9-02)		

number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: ANTIGENICS INC /DE/ - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Shares (1)	<u>(1)</u>	10/01/2008		А		3,028.702		<u>(1)</u>	(1)	Common Stock	3,028.702

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Levitsky Hyam C/O ANTIGENICS INC. 162 FIFTH AVENUE, SUITE 900 NEW YORK, NY 10010	Х							
Signatures								
Christine M. Klaskin, by Power of Attorney	10/03/2008							
<u>**</u> Signature of Reporting Person		Date						
E		_						

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Acquired under the Antigenics Inc. Directors' Deferred Compensation Plan. Deferred Shares represent an equal amount of shares of the(1) Company's common stock to be distributed with the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.